Skip to content Skip to footer
Subscribe Now
CXO TALKS

Cytek Biosciences on Redefining Flow Cytometry Excellence | PharmaShots CXO Talks

What happens when cell analysis moves beyond simply measuring more to understanding more? In the latest episode of PharmaShots CXO Talks, Wenbin Jiang, CEO and Chairman of the Board, and William McCombe, Chief Financial Officer, Cytek Biosciences, explore how advances in flow cytometry, AI, imaging, and cloud-based analytics are reshaping the way researchers understand cells.…
September 16, 2026

Read more

NEWS

Natera Acquires Foresight Diagnostics for ~$450M to Strengthen Ultrasensitive MRD Testing in Solid Tumors & Lymphoma

Shots: Natera has acquired Foresight Diagnostics, adding its PhasED-Seq phased variant technology with LOD95 of 0.3ppm & detection below 0.1ppm, further enhancing Natera’s capabilities in solid tumor MRD and expanding its IP portfolio of >500 issued/pending patents As per the agreement, Natera completed the acquisition in an all-stock transaction incl. $275M upfront & up to…
December 8, 2025

Read more